Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Completed · Not applicable
Conditions studied: Sarcoma
In brief
RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and may have a role in causing Kaposi's sarcoma. Valganciclovir is an antiviral drug that acts against many types of herpesviruses and may be an effective treatment for Kaposi's sarcoma. PURPOSE: This clinical trial is studying how well valganciclovir works in treating patients with classic non-HIV-associated Kaposi's sarcoma.
Key facts
- Study ID
- NCT00096538
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 6
- Starts
- 2004-04-01
- Expected to finish
- 2008-02-01
- Last updated by the study team
- 2015-11-25
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan - Kettering Cancer Center — New York, New York, United States
- New York Weill Cornell Cancer Center at Cornell University — New York, New York, United States
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.